How Long You May Need To Walk Outside To See A Boost In Your Mental Health
A new small study published in Molecular Psychiatry further underscores this. The study found that a one-hour nature walk reduces stress when compared to a one-hour walk in a bustling city environment.
The study followed 63 people who were randomly assigned a nature walk or an urban walk. The nature walk took place in a forest in Berlin and the urban walk took place on a busy street in the city.
Participants were instructed not to check their phones or stop in stores while on their walk. They were given a bagged lunch and a phone with a 30-minute timer that instructed them to turn around.
Before the walk, participants filled out a questionnaire and then underwent an fMRI scan that measured two tasks.
The first task measured brain activity during a 'fearful faces task,' in which participants were shown 15 female and 15 male faces that either had a neutral or scared expression. The second task measured was brain activity during an 'Montreal Imaging Stress Task,' which is designed to create a level of stress in participants. During the task, participants had a set amount of time to solve challenging arithmetic problems.
After the walk, participants filled out another questionnaire and underwent another fMRI scan that measured the same tasks they conducted before their walk.
The results showed that nature significantly improved people's stress levels.
The study found that those who took part in the 60-minute nature walk experienced lower stress levels following their time outside.
'The results of our study show that after only [a] one-hour walk in nature, activity in brain regions involved in stress processing decreases,' Sonja Sudimac, the lead author of the study, told Medical News Today.
Particularly, the researchers found the brain's amygdala activity (which is responsible for our stress and fear response) decreased in those who were in the nature walk group.
This decrease was not seen in people who completed the city walk. According to the study, urban environments can negatively impact one's mental health, leading to increased rates of anxiety, depression and mood disorders. (Just think about the stress that comes with frequently honking horns, running to catch a bus or dealing with long lines just to get some groceries.)
In fact, other studies show that mental health can suffer in urban areas because of the crowded nature of cities and, in general, the increased amount of stressors throughout the environment.
It's worth noting that the study had a few limitations: All participants were from a similar background and the study could not control who participants saw on their walk. So, for example, if someone on a walk in the forest saw someone relaxing on their day off, it could have further decreased the stress response in the participant.
This study also only focused on the benefits of a one-hour-long nature walk — it's unclear if the same positive results would occur in a shorter amount of time. But, Sudimac told Medical News Today that there is evidence that levels of the stress hormone cortisol decrease after a 15-minute nature walk, which would make a version of this study that looked at shorter walks interesting.
Plus, outside of this study, there is extensive research on the positive effects of the outdoors, so it's not hard to conclude that even a few minutes outside is better than nothing.
Beyond decreased stress, nature has other benefits.
Dr. Tamanna Singh, co-director of the sports cardiology center at Cleveland Clinic, previously told HuffPost that walking in nature has additional mental health benefits, too.
'Many of us just don't get enough of nature, and a walk is a fantastic way to focus on taking in air, walking on mother earth, listening to the leaves rustling, the birds chirping, essentially 'forest bathing,'' she said.
Forest bathing has a number of benefits, she pointed out: It can help improve mindfulness, can be meditative and can improve your breathing.
Spending time outside has also been shown to improve your sleep, increase your creativity and boost your immune function.
Whether you live in a city or a rural area, try to prioritize nature walks.
The results are clear: Spending time in nature is good for your mental health. But don't be discouraged if you live in a city. It's important to note that the study's nature walk took place in an urban forest within the city of Berlin.
So, even just a walk through your local park or nature reserve can help you achieve a sense of calm. The key is getting around green space ― and dedicating 60 minutes to moving your body and soaking up the outdoors.
The headline and subheadline of this story have been updated to better reflect the study.
Related...
This Type Of Walking May Drastically Improve Your Heart Function
How Much You Need To Walk Every Day To Cut Your Risk Of Heart Disease
Should We All Be Squatting More?
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


CBS News
31 minutes ago
- CBS News
Century-old shipwreck in North Sea is filled with stash of rare oysters in bid to revive marine species
A cargo ship lying at the bottom of the sea off the Belgian coast has been fitted with a new treasure chest: a stash of rare flat oysters. Molluscs have mostly disappeared from the North Sea due to human activity, including overfishing. Now, a Belgian project is trying to reintroduce it in a move scientists believe will help boost other marine species. "We have to bring them back because they are essential elements in our marine ecosystems," Vicky Stratigaki, an engineer working on the restoration project, told AFP. In mid-July, a load of 200,000 oyster larvae attached to biodegradable materials was deposited about 100 feet under the sea in the ship's hull. The environmental project, named Belreefs, aims to turn the wreckage into a biodiversity sanctuary. Flat oysters form reefs that purify water and that other sea animals, from fish to algae, use as breeding and feeding grounds, explained Stratigaki. "There is a lot of predation in the sea, it's a wild environment," she said, with about 30,000 of the oyster larvae expected to survive their first year at sea. "Then they will start reproducing, extending the reef and also supporting the biodiversity of the reef." The laying of the oyster stash is the culmination of two years' work for the Belgian government project, which is supported by European Union funding. "Until around the 1850s, the North Sea and the European waters were full of these oyster reefs," Stratigaki explained. Then overfishing, the spreading of an imported parasite called Bonamia and "climatic adverse effects" caused them to disappear, she said. The 1906 wreckage, located about 20 miles off the coastal city of Ostend, was selected to house the pilot as fishing and other disruptive activities are banned around it. "In Belgium every wreck that is for more than one hundred years on the sea bottom gets protected automatically as cultural heritage, because it's nice for divers to go there," said Merel Oeyen, a marine environment expert at the Belgian ministry of health. "It's also a hot spot for biodiversity." A 2023 paper published in BioScience found that shipwrecks provide important ecological resources for a wide variety of organisms, from tiny microbes to large marine creatures. "Small fish and mobile crustaceans often find shelter in the crevices of the sunken material, and larger baitfish and predators use shipwrecks as feeding grounds and rest stops as they swim from one place to another," according to NOAA, which helped conduct the study. However, scientists also warned shipwreck can also cause damage to existing marine life in the area, or carry harmful cargo, such as oil. Still, the study's author, Avery Paxton, said shipwrecks can have "second lives" as homes to a variety of marine life. "A ship's transformation from an in-service vessel into a thriving metropolis for marine life has a fairy-tale quality to it," Paxton said in an article published by the Washington Post after the study was released.


Medscape
an hour ago
- Medscape
Dex: Transforming Pediatric Tonsillectomy Outcomes
TOPLINE: The administration of dexmedetomidine was associated with reduced perioperative requirements for opioids in pediatric tonsillectomy, along with lower likelihoods of emergence delirium and postoperative nausea and vomiting. METHODOLOGY: Researchers conducted a systematic review and meta-analysis of 16 randomized controlled trials involving 1634 pediatric patients (mean age range, 4-8.5 years) undergoing tonsillectomy with or without adenoidectomy under general anesthesia. Dexmedetomidine was administered intravenously during the procedure at doses ranging from 0.1 to 4.0 μg/kg alongside opioids compared with opioids alone. The primary outcome was perioperative requirements for opioids, measured in oral morphine equivalents. Secondary outcomes included incidences of perioperative respiratory adverse events (including severe or sustained cough), emergence delirium (determined using the Pediatric Anesthesia Emergence Delirium Scale), and postoperative nausea and vomiting. TAKEAWAY: The administration of dexmedetomidine was associated with reduced perioperative requirements for opioids (mean difference, -0.25 mg/kg; 95% CI, -0.36 to -0.13), as analyzed from seven studies. The likelihood of emergence delirium was lower with the use of dexmedetomidine (risk ratio [RR], 0.24; 95% CI, 0.08-0.71), as analyzed from three trials. For every 0.5 μg/kg increase in the dose of dexmedetomidine, the RR for emergence delirium decreased by approximately 87%. The administration of dexmedetomidine was associated with a lower likelihood of postoperative nausea and vomiting or postoperative vomiting (RR, 0.48; 95% CI, 0.35-0.66; 12 trials). IN PRACTICE: 'Dexmedetomidine may improve the perioperative course of children undergoing tonsillectomy, as moderate certainty evidence indicates that it decreases perioperative opioid requirements, and moderate certainty evidence suggests it reduces the rate of emergence delirium, with dose-dependent effects, when compared with control,' the researchers of the study reported. SOURCE: The study was led by Julia M. Olsen, MD, of the Department of Anesthesia and Pain Medicine at The Hospital for Sick Children in Toronto, Ontario, Canada. It was published online on July 11, 2025, in the Canadian Journal of Anesthesia. LIMITATIONS: The publication bias could not be assessed due to a limited number of trials. The certainty of evidence was affected by significant heterogeneity in the primary outcome. Subgroup analysis could not be performed due to lack of data, and the small sample size and zero event rates for some outcomes in many trials hindered mediation analyses. DISCLOSURES: This study did not receive any specific funding. No conflicts of interest were declared. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.


Medscape
an hour ago
- Medscape
Safe to Skip Postop Radioiodine in Low-Risk Thyroid Cancers?
TOPLINE: A recent phase 3 trial found that 5-year recurrence-free survival was similar among patients who did and did not receive postoperative radioiodine, indicating the treatment can be safely avoided in patients with low-risk differentiated thyroid cancer — specifically those with pT1, pT2, and N0 or Nx tumors who have no adverse features after total thyroidectomy. METHODOLOGY: Although now used less often, total thyroidectomy followed by radioiodine has traditionally been the standard of care for treating differentiated thyroid cancer. Observational studies and the ESTIMABL2 trial , published in 2022, suggested that patients with low-risk disease could safely skip radioiodine, but confirmatory evidence was still needed. The recent randomized, noninferiority, phase 3 IoN trial aimed to answer this question. The study involved patients at 33 cancer centers in the UK who underwent complete resection following total thyroidectomy and stage pT1, pT2, pT3, or pT3a disease. Researchers randomly assigned 504 patients (77% women) to receive (n = 253) or not receive (n = 251) postoperative radioiodine. Patients underwent neck ultrasound scans annually and serum thyroglobulin measurements every 6 months. The median follow-up was 6.7 years. The primary outcome was 5-year disease-free survival, defined as the absence of locoregional recurrent or residual structural disease, distant metastases, or death from thyroid cancer. Noninferiority was assessed with a margin of 5 percentage points. Overall, 47% of patients had pT1 tumors, 44% had pT2, and 9% had pT3 or pT3a; 91% of patients had N0 or Nx disease, and 9% had N1a disease. TAKEAWAY: Overall, 17 recurrences were reported — 8 in the no-radioiodine group and 9 in the radioiodine group. The 5-year recurrence-free rate was 97.9% in the no-radioiodine group vs 96.3% in the radioiodine group, with an absolute risk difference of 0.5 percentage points (P for noninferiority = .033), highlighting the noninferiority of omitting radioiodine. Higher recurrence rates were observed in patients with pT3 or pT3a tumors than in those with pT1 or pT2 tumors (9% vs 3%) and in patients with N1a tumors than in those with N0 or Nx tumors (13% vs 2%). Additionally, baseline postsurgical thyroglobulin levels ≥ 2 ng/mL were associated with a higher risk for recurrence (hazard ratio, 12.75; P < .0001). Adverse events were comparable between the no-radioiodine and radioiodine groups, with fatigue (25% vs 28%), lethargy (14% in both), and dry mouth (10% vs 9%) being the most common. No treatment-related deaths or deaths from thyroid cancer were reported. But a total of eight patients died — an equal number in both groups. In the no-radioiodine group, deaths were due to two new primary cancers, one myocardial infarction, and one liver failure. In the radioiodine group, one death was due to bowel cancer and three due to vascular or unknown causes. IN PRACTICE: IoN and ESTIMABL2 together 'offer strong and complementary evidence showing' that postoperative radioiodine can be avoided in patients with low-risk differentiated thyroid cancer — more specifically, pT1 or pT2 tumors with N0 nodal status and no other adverse features, the study authors concluded. Although the evidence for or against radioiodine in patients with pT3, pT3a, or N1a tumors was deemed 'insufficient,' the authors concluded that 'most patients worldwide with low-risk differentiated thyroid cancer' can now safely avoid radioiodine. SOURCE: This study, led by Ujjal Mallick, Freeman Hospital, Newcastle upon Tyne, England, was published online in The Lancet. LIMITATIONS: Patients had relatively few recurrences, and the findings may not be applicable to the youngest patients. Additionally, molecular data (eg, on BRAF and TERT mutations) were not routinely collected from patients. DISCLOSURES: This study was funded by Cancer Research UK. One author reported receiving honoraria from Esai and the British Medical Ultrasound Society for presenting treatment options for differentiated thyroid cancer. Another author reported receiving honoraria from Esai for presenting treatment options for differentiated thyroid cancer. All other authors declared having no competing interests. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.